Lv2
146 积分 2022-02-17 加入
Controlled Fab-arm exchange for the generation of stable bispecific IgG1
24天前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
1个月前
已关闭
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease
3个月前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
3个月前
已完结
Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma
4个月前
已完结
Which One Is Better for Relapsed/ Refractory Acute Myeloid Leukemia: Daratumumab or CD38-Targeted Chimeric Antigen Receptor T-Cell Therapy?
4个月前
已关闭
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
4个月前
已完结
皖公网安备34019202002308
